BioHarvest Sciences Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy BHST?
Source: seekingalpha
- Revenue Growth: In Q1 2026, BioHarvest reported an 8% year-over-year revenue increase to $8.5 million from $7.9 million, indicating robust market performance and growth potential.
- Strategic Transition: The company implemented a new two-lens strategy with a leadership transition aimed at optimizing the performance of its two business segments, enhancing overall operational efficiency and market competitiveness.
- Contract Signing: The CDMO division signed a $1.2 million Stage 2 contract, ensuring 20% ownership of developed products, thereby creating a long-term royalty revenue stream for the company.
- Financial Outlook: Revenue guidance for 2026 for the D2C business is projected between $38 million and $42 million, with adjusted EBITDA profit expected to range from $0.5 million to $2 million, despite a one-time revenue decline in Q1, the company anticipates quarter-over-quarter revenue growth for the remainder of the year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHST
Wall Street analysts forecast BHST stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.160
Low
12.00
Averages
13.00
High
14.00
Current: 4.160
Low
12.00
Averages
13.00
High
14.00
About BHST
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioHarvest Sciences Reports Q1 Financial Results
- Net Loss Overview: BioHarvest Sciences reported a Q1 net loss of $2.6 million, or $0.11 per basic and diluted share, which is an increase from last year's loss of $2.3 million, or $0.13 per share, indicating challenges in cost management and operational efficiency.
- Revenue Growth: The company achieved Q1 revenue of $8.5 million, reflecting an 8% year-over-year increase, which, despite the widening losses, suggests stable market demand that could lay the groundwork for future profitability.
- Annual Revenue Guidance: BioHarvest Sciences maintains its annual revenue guidance in the range of $42 million to $48 million, demonstrating confidence in future performance despite short-term losses, and indicating a positive outlook for long-term growth potential.
- Market Reaction: Although the Q1 report shows an increase in losses, the market's response to the revenue growth could influence the stock price trajectory, prompting investors to closely monitor subsequent financial performance and strategic initiatives.
See More
BioHarvest Sciences Q1 2026 Earnings Call Insights
- Revenue Growth: In Q1 2026, BioHarvest reported an 8% year-over-year revenue increase to $8.5 million from $7.9 million, indicating robust market performance and growth potential.
- Strategic Transition: The company implemented a new two-lens strategy with a leadership transition aimed at optimizing the performance of its two business segments, enhancing overall operational efficiency and market competitiveness.
- Contract Signing: The CDMO division signed a $1.2 million Stage 2 contract, ensuring 20% ownership of developed products, thereby creating a long-term royalty revenue stream for the company.
- Financial Outlook: Revenue guidance for 2026 for the D2C business is projected between $38 million and $42 million, with adjusted EBITDA profit expected to range from $0.5 million to $2 million, despite a one-time revenue decline in Q1, the company anticipates quarter-over-quarter revenue growth for the remainder of the year.
See More
BioHarvest Advances CDMO Program to Stage 2 with $1.125M Agreement
- Project Advancement: BioHarvest's CDMO division has successfully completed Stage 1, establishing a stable saffron cell bank, marking the advancement of its $1.125 million multi-stage development agreement to Stage 2, which is expected to drive future product development for nutraceutical and culinary applications.
- Market Potential: Saffron, one of the world's most expensive botanicals, can command prices up to $10,000 per kilogram, with strong demand particularly in the nutraceutical and culinary sectors, anticipating a nearly $500 million global market by 2025.
- Sustainable Production: BioHarvest's Botanical Synthesis platform enables the production of saffron-derived compounds without traditional farming, ensuring product consistency, purity, and long-term supply stability, further solidifying its market position in the CDMO space.
- Equity and Royalties: Under the agreement, BioHarvest will retain a 25% ownership stake in the saffron composition being developed and will earn manufacturing royalties from any future saffron compounds produced, reflecting its strategy to participate in downstream value creation.
See More
BioHarvest Sciences Leadership Transition
- Leadership Change: BioHarvest Sciences announced that Dr. Zaki Rakib has taken over as CEO, consolidating operational control of the company's contract development and manufacturing organization, aiming to enhance management efficiency and achieve strategic goals.
- Former CEO's Role Shift: Ilan Sobel, who served as CEO since 2020, has transitioned to a board member role focused on advancing the direct-to-consumer (D2C) business, indicating the company's emphasis on D2C models and future growth expectations.
- Strategic Focus Shift: This leadership transition not only optimizes the internal structure but also reflects BioHarvest Sciences' keen response to market competition and consumer demands, which may influence its future business direction.
- Market Reaction Anticipation: With the new leadership in place, the market is optimistic about BioHarvest Sciences' future performance, particularly in expanding its D2C business, which could attract more investor attention.
See More
Multiple Companies Set to Report Earnings
- Nike Earnings Forecast: Nike (NKE) is expected to report an earnings per share of $0.29 for the quarter ending February 28, 2026, representing a 46.30% decrease compared to the same quarter last year, indicating increased competitive pressure despite beating expectations consistently over the past year.
- PVH Earnings Outlook: PVH is forecasting an earnings per share of $3.30 for the quarter ending January 31, 2026, reflecting a modest 0.92% increase year-over-year, demonstrating its stable market position as it has consistently exceeded market expectations in the past year.
- RH Earnings Growth: RH anticipates an earnings per share of $2.21 for the quarter ending January 31, 2026, marking a significant 39.87% year-over-year increase, showcasing strong business growth potential that may attract more investor interest.
- nCino Earnings Prediction: nCino expects an earnings per share of $0.06 for the quarter ending January 31, 2026, representing a remarkable 250.00% increase compared to the same quarter last year, which could help restore market confidence after previous underperformance.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
BioHarvest Sciences Reports Q1 Financial Results
- Net Loss Overview: BioHarvest Sciences reported a Q1 net loss of $2.6 million, or $0.11 per basic and diluted share, which is an increase from last year's loss of $2.3 million, or $0.13 per share, indicating challenges in cost management and operational efficiency.
- Revenue Growth: The company achieved Q1 revenue of $8.5 million, reflecting an 8% year-over-year increase, which, despite the widening losses, suggests stable market demand that could lay the groundwork for future profitability.
- Annual Revenue Guidance: BioHarvest Sciences maintains its annual revenue guidance in the range of $42 million to $48 million, demonstrating confidence in future performance despite short-term losses, and indicating a positive outlook for long-term growth potential.
- Market Reaction: Although the Q1 report shows an increase in losses, the market's response to the revenue growth could influence the stock price trajectory, prompting investors to closely monitor subsequent financial performance and strategic initiatives.
See More
BioHarvest Sciences Q1 2026 Earnings Call Insights
- Revenue Growth: In Q1 2026, BioHarvest reported an 8% year-over-year revenue increase to $8.5 million from $7.9 million, indicating robust market performance and growth potential.
- Strategic Transition: The company implemented a new two-lens strategy with a leadership transition aimed at optimizing the performance of its two business segments, enhancing overall operational efficiency and market competitiveness.
- Contract Signing: The CDMO division signed a $1.2 million Stage 2 contract, ensuring 20% ownership of developed products, thereby creating a long-term royalty revenue stream for the company.
- Financial Outlook: Revenue guidance for 2026 for the D2C business is projected between $38 million and $42 million, with adjusted EBITDA profit expected to range from $0.5 million to $2 million, despite a one-time revenue decline in Q1, the company anticipates quarter-over-quarter revenue growth for the remainder of the year.
See More
BioHarvest Advances CDMO Program to Stage 2 with $1.125M Agreement
- Project Advancement: BioHarvest's CDMO division has successfully completed Stage 1, establishing a stable saffron cell bank, marking the advancement of its $1.125 million multi-stage development agreement to Stage 2, which is expected to drive future product development for nutraceutical and culinary applications.
- Market Potential: Saffron, one of the world's most expensive botanicals, can command prices up to $10,000 per kilogram, with strong demand particularly in the nutraceutical and culinary sectors, anticipating a nearly $500 million global market by 2025.
- Sustainable Production: BioHarvest's Botanical Synthesis platform enables the production of saffron-derived compounds without traditional farming, ensuring product consistency, purity, and long-term supply stability, further solidifying its market position in the CDMO space.
- Equity and Royalties: Under the agreement, BioHarvest will retain a 25% ownership stake in the saffron composition being developed and will earn manufacturing royalties from any future saffron compounds produced, reflecting its strategy to participate in downstream value creation.
See More
BioHarvest Sciences Leadership Transition
- Leadership Change: BioHarvest Sciences announced that Dr. Zaki Rakib has taken over as CEO, consolidating operational control of the company's contract development and manufacturing organization, aiming to enhance management efficiency and achieve strategic goals.
- Former CEO's Role Shift: Ilan Sobel, who served as CEO since 2020, has transitioned to a board member role focused on advancing the direct-to-consumer (D2C) business, indicating the company's emphasis on D2C models and future growth expectations.
- Strategic Focus Shift: This leadership transition not only optimizes the internal structure but also reflects BioHarvest Sciences' keen response to market competition and consumer demands, which may influence its future business direction.
- Market Reaction Anticipation: With the new leadership in place, the market is optimistic about BioHarvest Sciences' future performance, particularly in expanding its D2C business, which could attract more investor attention.
See More
Multiple Companies Set to Report Earnings
- Nike Earnings Forecast: Nike (NKE) is expected to report an earnings per share of $0.29 for the quarter ending February 28, 2026, representing a 46.30% decrease compared to the same quarter last year, indicating increased competitive pressure despite beating expectations consistently over the past year.
- PVH Earnings Outlook: PVH is forecasting an earnings per share of $3.30 for the quarter ending January 31, 2026, reflecting a modest 0.92% increase year-over-year, demonstrating its stable market position as it has consistently exceeded market expectations in the past year.
- RH Earnings Growth: RH anticipates an earnings per share of $2.21 for the quarter ending January 31, 2026, marking a significant 39.87% year-over-year increase, showcasing strong business growth potential that may attract more investor interest.
- nCino Earnings Prediction: nCino expects an earnings per share of $0.06 for the quarter ending January 31, 2026, representing a remarkable 250.00% increase compared to the same quarter last year, which could help restore market confidence after previous underperformance.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
